Greater Sensitivity to Multiple Sclerosis Disability Worsening and Progression Events Using a Roving Versus a Fixed Reference Value in a Prospective Cohort Study
Overview
Authors
Affiliations
Background: Confirmed Expanded Disability Status Scale (EDSS) progression occurring after a fixed-study entry baseline is a common measure of disability increase in relapsing-remitting multiple sclerosis (RRMS) studies but may not detect all disability progression events, especially those unrelated to overt relapses.
Objective: To evaluate possible measures of disability progression unrelated to relapse using EDSS data over ≈5.5 years from the Tysabri Observational Program (TOP).
Methods: TOP is an ongoing, prospective, open-label study in RRMS patients receiving intravenous 300 mg natalizumab every 4 weeks. Measures of increasing disability were assessed using as a reference either study baseline score or a "roving" system that resets the reference score after ⩾24- or ⩾48-week confirmation of a new score.
Results: This analysis included 5562 patients. Approximately 70% more EDSS progression events unrelated to relapse and 50% more EDSS worsening events overall were detected with a roving reference score (cumulative probability: 17.6% and 29.7%, respectively) than with a fixed reference baseline score (cumulative probability: 10.1% and 20.3%, respectively).
Conclusion: In this long-term observational RRMS dataset, a roving EDSS reference value was more efficient than a study baseline EDSS reference in detecting progression/worsening events unrelated to relapses and thus the transition to secondary progressive disease.
Krajnc N, Hofer L, Fottinger F, Dal-Bianco A, Leutmezer F, Kornek B Eur J Neurol. 2024; 32(1):e16529.
PMID: 39529542 PMC: 11622274. DOI: 10.1111/ene.16529.
Reeves J, Bartnik A, Jakimovski D, Mohebbi M, Bergsland N, Salman F Neurology. 2024; 103(10):e210004.
PMID: 39447104 PMC: 11509899. DOI: 10.1212/WNL.0000000000210004.
Multiple sclerosis: emerging epidemiological trends and redefining the clinical course.
Portaccio E, Magyari M, Kubala Havrdova E, Ruet A, Brochet B, Scalfari A Lancet Reg Health Eur. 2024; 44:100977.
PMID: 39444703 PMC: 11496978. DOI: 10.1016/j.lanepe.2024.100977.
Simone M, Lucisano G, Guerra T, Paolicelli D, Rocca M, Morra V J Neurol. 2024; 271(10):6782-6790.
PMID: 39179712 PMC: 11447039. DOI: 10.1007/s00415-024-12638-0.
Ciccarelli O, Barkhof F, Calabrese M, De Stefano N, Eshaghi A, Filippi M Neurology. 2024; 103(1):e209444.
PMID: 38889384 PMC: 11226318. DOI: 10.1212/WNL.0000000000209444.